Histamine dihydrochloride topical - EpiCept Corporation

Drug Profile

Histamine dihydrochloride topical - EpiCept Corporation

Alternative Names: MaxDerm; MaxDerm gel; MX 1006; MX 8899

Latest Information Update: 26 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Maxim Pharmaceuticals
  • Class Antineoplastics; Antivirals; Imidazoles; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Histamine H2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Burns; Conjunctivitis; Herpes simplex virus infections; Herpes zoster; Pressure ulcer; Radiodermatitis; Stomatitis

Most Recent Events

  • 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
  • 01 Mar 2004 Phase-II clinical trials in Burns in USA (Topical)
  • 01 Mar 2004 Phase-II clinical trials in Conjunctivitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top